- Ariad Pharmaceuticals (NASDAQ:ARIA -8.8%) eases on 50% higher volume. The company reported its preliminary 2014 results and objectives for this year this morning. Investors appear unimpressed as shares have been underwater since then.
- One of the goals is to achieve sustained profitability in 2018 driven by product sales of more than $400M.
- Chairman & CEO Dr. Harvey Berger didn't help matters with his interview with CNBC's Meg Tirrell. He appeared confused and uncomfortable.